- Home
- ATRO vs NRIX Comparison
ATRO vs NRIX Comparison
Compare ATRO & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATRO
- NRIX
- Stock Information
- Founded
- ATRO 1968
- NRIX 2009
- Country
- ATRO United States
- NRIX United States
- Employees
- ATRO N/A
- NRIX N/A
- Industry
- ATRO Military/Government/Technical
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- ATRO Industrials
- NRIX Health Care
- Exchange
- ATRO Nasdaq
- NRIX Nasdaq
- Market Cap
- ATRO 844.1M
- NRIX 908.0M
- IPO Year
- ATRO N/A
- NRIX 2020
- Fundamental
- Price
- ATRO $33.57
- NRIX $11.84
- Analyst Decision
- ATRO Hold
- NRIX Strong Buy
- Analyst Count
- ATRO 1
- NRIX 16
- Target Price
- ATRO $32.00
- NRIX $30.44
- AVG Volume (30 Days)
- ATRO 574.9K
- NRIX 840.0K
- Earning Date
- ATRO 07-31-2025
- NRIX 07-10-2025
- Dividend Yield
- ATRO N/A
- NRIX N/A
- EPS Growth
- ATRO N/A
- NRIX N/A
- EPS
- ATRO N/A
- NRIX N/A
- Revenue
- ATRO $816,288,000.00
- NRIX $56,417,000.00
- Revenue This Year
- ATRO $8.33
- NRIX $16.69
- Revenue Next Year
- ATRO $5.89
- NRIX N/A
- P/E Ratio
- ATRO N/A
- NRIX N/A
- Revenue Growth
- ATRO 13.73
- NRIX N/A
- 52 Week Low
- ATRO $14.13
- NRIX $8.18
- 52 Week High
- ATRO $36.32
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- ATRO 60.18
- NRIX 54.06
- Support Level
- ATRO $32.61
- NRIX $11.17
- Resistance Level
- ATRO $34.72
- NRIX $12.40
- Average True Range (ATR)
- ATRO 1.55
- NRIX 0.62
- MACD
- ATRO -0.35
- NRIX -0.07
- Stochastic Oscillator
- ATRO 28.20
- NRIX 34.90
About ATRO Astronics Corporation
Astronics Corp supplies products to the aerospace, defense, and electronics industries. The company has two reportable segments namely Aerospace and Test Systems. The aerospace segment serves three primary markets: military, commercial transport, and General Aviation. The Test Systems segment serves the aerospace, defense, and semiconductor markets. The company generates a majority of its revenue from the Aerospace segment. Geographically, it generates a majority of its revenue from the United States.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.